Form 8-K · Current report
Gilead Sciences 8-K, filed Oct 29, 2026
- Filed
- CIK
- 0000882095
- Accession no.
- 0000882095-26-000037
Summary
Gilead Sciences reported third-quarter 2026 product sales of $8.3 billion, up 13% year over year, and raised its full-year 2026 product sales guidance to $31.0–$31.3 billion from $30.1–$30.4 billion. The company also said the FDA approved Bixlenvo for HIV treatment in virologically suppressed adults and expanded voluntary licensing for lenacapavir.
Key points
- Total Q3 2026 product sales rose 13% to $8.3 billion; excluding Veklury, product sales rose 16% to $8.2 billion.
- GAAP diluted EPS was $1.94 versus $2.43 a year earlier, while non-GAAP diluted EPS was $2.55 versus $2.47.
- HIV product sales increased 18% to $6.2 billion, with Biktarvy sales up 10% to $4.1 billion.
- The FDA approved Bixlenvo for HIV treatment in virologically suppressed adults, and Gilead expanded royalty-free voluntary licensing for lenacapavir to include investigational once-yearly HIV prevention.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On October 29, 2026, Gilead Sciences, Inc., a Delaware corporation (“Gilead”), announced its financial results for the quarter ended September 30, 2026. A copy of the press release is filed as Exhibit 99.1 to this report. Gilead has presented certain financial information in accordance with U.S. generally accepted accounting principles (“GAAP”) and also on a non-GAAP basis. Management believes this non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.